Bradycardia · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
Sugammadex (any dose) probably leads to lower bradycardia compared with neostigmine (any dose) (moderate certainty).
1 finding from 1 review
Number of patients with postoperative nausea and vomiting (24 hours postoperatively) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
Sugammadex (any dose) may leads to lower PONV compared with neostigmine (any dose) (low certainty).
1 finding from 1 review
Overall signs of postoperative residual paralysis · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
Sugammadex (any dose) probably leads to lower overall signs of postoperative residual paralysis compared with neostigmine (any dose) (moderate certainty).
1 finding from 1 review
Risk of serious adverse eventsb · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
Sugammadex (any dose) showed no clear difference in risk of serious adverse eventsb compared with neostigmine (any dose) (low certainty).
1 finding from 1 review
Recovery timea from second twitch (T2) to train‐of‐four ratio (TOFR) > 0.9 (moderate block) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recovery timea from post‐tetanic count (PTC) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of composite adverse eventsb · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
Sugammadex (any dose) probably leads to lower risk of composite adverse eventsb compared with neostigmine (any dose) (moderate certainty).
1 finding from 1 review